Rockefeller Capital Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Rockefeller Capital Management's NKTR Position: Q3 2026 in Review
Rockefeller Capital Management held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 200 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4100.
Rockefeller Capital Management first reported a position in NKTR in Q1 2019 and has held it in 13 quarters since. The position peaked at $14K in Q2 2026. 204 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Rockefeller Capital Management held 200 shares of Nektar Therapeutics worth $12.1K as of Q3 2026.
- Rockefeller Capital Management left its Nektar Therapeutics share count unchanged in Q3 2026.
- Nektar Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4100 holding.
- Rockefeller Capital Management first reported a position in Nektar Therapeutics in Q1 2019 and has held it in 13 quarters since.
- Rockefeller Capital Management's Nektar Therapeutics position peaked at $14K in Q2 2026.
- 204 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.